Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359727 | 1.00 | NPC1 (0.49) | NPC1MEN1KMT2AADRB3ADRB2 | |
| SCHEMBL5359732 | 1.00 | NPC1 (0.49) | NPC1MEN1KMT2AADRB3ADRB2 | |
| SCHEMBL5371441 | 0.95 | MEN1 (0.45) | NPC1MEN1KMT2AADRB3ADRB2 | |
| SCHEMBL5359451 | 0.95 | MEN1 (0.45) | NPC1MEN1KMT2AADRB3ADRB2 | |
| SCHEMBL5359446 | 0.95 | MEN1 (0.45) | NPC1MEN1KMT2AADRB3ADRB2 | |
| SCHEMBL5367810 | 0.95 | NPC1 (0.44) | NPC1MEN1KMT2AADRB3ADRB2 | |
| SCHEMBL1381904 | 0.95 | NPC1 (0.56) | NPC1MEN1KMT2AADRB3ADRB2 | |
| SCHEMBL5361309 | 0.95 | NPC1 (0.44) | NPC1MEN1KMT2AADRB3ADRB2 | |
| SCHEMBL5366687 | 0.95 | NPC1 (0.56) | NPC1MEN1KMT2AADRB3ADRB2 | |
| SCHEMBL1381901 | 0.95 | NPC1 (0.56) | NPC1MEN1KMT2AADRB3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | claimed |
| US-20050107377-A1 | Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTIALS INC. (US) | 2005-05-19 | — | — | US | claimed |
| EP-1216244-B1 | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMA INC (US) | 2003-08-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107377-A1 | Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | DRD4, DRD2, DRD1 | NPC1 2469/4885MEN1 4880/4885KMT2A 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.